- Home
- FBIO
as 11-15-2024 4:00pm EST
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BAY HARBOR ISLANDS |
| Market Cap: | 39.4M | IPO Year: | N/A |
| Target Price: | $16.33 | AVG Volume (30 days): | 605.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.36 - $4.43 | Next Earning Date: | 11-14-2024 |
| Revenue: | $81,501,000 | Revenue Growth: | 31.51% |
| Revenue Growth (this year): | -1.56% | Revenue Growth (next year): | 81.63% |
Latest Fortress Biotech Inc. News
FBIO Breaking Stock News: Dive into FBIO Ticker-Specific Updates for Smart Investing
Simply Wall St.
12 hours ago
Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations
Associated Press Finance
3 days ago
Fortress Biotech: Q3 Earnings Snapshot
GlobeNewswire
3 days ago
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
3 days ago
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
5 days ago
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
GlobeNewswire
5 days ago
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
5 days ago
Mustang Bio Receives Positive Listing Determination from Nasdaq
GlobeNewswire
10 days ago
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
Compare FBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FBIO Fortress Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.